乳腺增生病（Hyperplastic disease of breast， HDB）是我國育齡女性最常見的乳腺疾病，且發(fā)病率呈逐年上升趨勢。青春期至絕經(jīng)期間均可發(fā)病，且近年來發(fā)病年齡呈低齡化，其惡變率隨年齡增長而逐漸增加。HDB與乳腺癌有共同的危險因素，癌變危險性較正常人高，尤其是乳腺不典型增生已被公認為乳腺癌的癌前病變，所以HDB的危害不容小覷?，F(xiàn)代醫(yī)學、傳統(tǒng)醫(yī)學及二者結合治療HDB的各種方案中，藥物治療都起著至關重要的作用，不同藥物作用機制不同，甚至有些藥物作用機制尚不明確。綜述目前治療HDB的藥物及其具體作用機制，并探討其優(yōu)缺點，為進一步探索研發(fā)出新的抗HDB藥物提供較為全面及科學的參考。

Hyperplastic disease of breast (HDB) is the most common breast disease in women of childbearing age in China, and the incidence rate is increasing year by year. It can occur from puberty to menopause, and the age of onset is younger in recent years, and its malignant rate gradually increases with age. HDB and breast cancer have common risk factors, and the risk of cancer is higher than that of normal people. Especially breast atypical hyperplasia has been recognized as a precancerous lesion of breast cancer, so the harm of HDB should not be underestimated. Modern medicine, traditional medicine and the combination of the two in the treatment of HDB, drug treatment play a vital role, the mechanism of action of different drugs is different, and even some mechanisms of action of drugs are not clear. This article reviews the current treatment of HDB drugs and its specific mechanism of action, and explores its advantages and disadvantages, providing a more comprehensive and scientific reference for further exploration and development of new anti-HDB drugs.

國家自然科學基金項目（81573664）